Association of Aspirin Use With Major Bleeding in Patients With and Without Diabetes

被引:193
作者
De Berardis, Giorgia [1 ]
Lucisano, Giuseppe [1 ]
D'Ettorre, Antonio [1 ]
Pellegrini, Fabio [1 ,2 ]
Lepore, Vito [1 ,3 ]
Tognoni, Gianni [1 ]
Nicolucci, Antonio [1 ]
机构
[1] Consorzio Mario Negri Sud, Dept Clin Pharmacol & Epidemiol, I-66030 Santa Maria Imbaro, Italy
[2] IRCCS, Biostat Unit, San Giovanni Rotondo, Italy
[3] Univ Bari, Dept Neurosci, Bari, Italy
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2012年 / 307卷 / 21期
关键词
LOW-DOSE ASPIRIN; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PROTON PUMP INHIBITORS; RANDOMIZED CONTROLLED-TRIALS; EXPERT CONSENSUS DOCUMENT; OF-CARDIOLOGY FOUNDATION; CARDIOVASCULAR EVENTS; PRIMARY PREVENTION; RISK-FACTORS; SUBARACHNOID HEMORRHAGE;
D O I
10.1001/jama.2012.5034
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context The benefit of aspirin for the primary prevention of cardiovascular events is relatively small for individuals with and without diabetes. This benefit could easily be offset by the risk of hemorrhage. Objective To determine the incidence of major gastrointestinal and intracranial bleeding episodes in individuals with and without diabetes taking aspirin. Design, Setting, and Participants A population-based cohort study, using administrative data from 4.1 million citizens in 12 local health authorities in Puglia, Italy. Individuals with new prescriptions for low-dose aspirin (<= 300 mg) were identified during the index period from January 1, 2003, to December 31, 2008, and were propensity-matched on a 1-to-1 basis with individuals who did not take aspirin during this period. Main Outcome Measures Hospitalizations for major gastrointestinal bleeding or cerebral hemorrhage occurring after the initiation of antiplatelet therapy. Results There were 186 425 individuals being treated with low-dose aspirin and 186 425 matched controls without aspirin use. During a median follow-up of 5.7 years, the overall incidence rate of hemorrhagic events was 5.58 (95% CI, 5.39-5.77) per 1000 person-years for aspirin users and 3.60 (95% CI, 3.48-3.72) per 1000 person-years for those without aspirin use (incidence rate ratio [IRR], 1.55; 95% CI, 1.48-1.63). The use of aspirin was associated with a greater risk of major bleeding in most of the subgroups investigated but not in individuals with diabetes (IRR, 1.09; 95% CI, 0.97-1.22). Irrespective of aspirin use, diabetes was independently associated with an increased risk of major bleeding episodes (IRR, 1.36; 95% CI, 1.28-1.44). Conclusions In a population-based cohort, aspirin use was significantly associated with an increased risk of major gastrointestinal or cerebral bleeding episodes. Patients with diabetes had a high rate of bleeding that was not independently associated with aspirin use. JAMA. 2012;307(21):2286-2294 www.jama.com
引用
收藏
页码:2286 / 2294
页数:9
相关论文
共 41 条
  • [31] COX-1 sensitivity and thromboxane A2 production in type 1 and type 2 diabetic patients under chronic aspirin treatment
    Pulcinelli, Fabio M.
    Biasucci, Luigi M.
    Riondino, Silvia
    Giubilato, Simona
    Leo, Andrea
    Di Renzo, Livia
    Trifiro, Elisabetta
    Mattiello, Teresa
    Pitocco, Dario
    Liuzzo, Giovanna
    Ghirlanda, Giovanni
    Crea, Filippo
    [J]. EUROPEAN HEART JOURNAL, 2009, 30 (10) : 1279 - 1286
  • [32] Hospitalization for gastrointestinal adverse events attributable to the use of low-dose aspirin among patients 50 years or older also using non-steroidal anti-inflammatory drugs: a retrospective cohort study
    Rahme, E.
    Nedjar, H.
    Bizzi, A.
    Morin, S.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 26 (10) : 1387 - 1398
  • [33] De testimonio: on the evidence for decisions about the use of therapeutic interventions
    Rawlins, Michael
    [J]. LANCET, 2008, 372 (9656) : 2152 - 2161
  • [34] Association between aspirin and upper gastrointestinal complications:: Systematic review of epidemiologic studies
    Rodríguez, LAG
    Hernández-Diaz, S
    de Abajo, FJ
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 52 (05) : 563 - 571
  • [35] Proton pump inhibitors and hospital discharge rates for gastrointestinal events in Italy: A national ecological study
    Russo, Pierluigi
    Brutti, Chiara
    [J]. CLINICAL THERAPEUTICS, 2007, 29 (04) : 751 - 758
  • [36] Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases
    Serrano, P
    Lanas, A
    Arroyo, MT
    Ferreira, IJ
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2002, 16 (11) : 1945 - 1953
  • [37] Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis
    Siller-Matula, J. M.
    Jilma, B.
    Schroer, K.
    Christ, G.
    Huber, K.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2010, 8 (12) : 2624 - 2641
  • [38] Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs
    Weil, J
    Langman, MJS
    Wainwright, P
    Lawson, DH
    Rawlins, M
    Logan, RFA
    Brown, TP
    Vessey, MP
    Murphy, M
    Colin-Jones, DG
    [J]. GUT, 2000, 46 (01) : 27 - 31
  • [39] WHO Collaborating Centre for Drug Statistics Methodology, 2003, ATC IND DDDS
  • [40] Winkler WE, 1992, COMP ANAL RECORD LIN, P829